Literature DB >> 16883308

The challenges of Proteus syndrome: diagnosis and management.

Leslie Biesecker1.   

Abstract

Proteus syndrome (PS) is a disorder of patchy or mosaic postnatal overgrowth of unknown etiology. The onset of overgrowth typically occurs in infancy and can involve any tissue of the body. Commonly involved tissues include connective tissue and bone, skin, central nervous system, the eye, but it apparently can affect any tissue. Diagnosing of PS is difficult and the diagnostic criteria are controversial. Our group advocates stringent diagnostic criteria to facilitate research and appropriate clinical care. The benefit of strict criteria is that they define a clinical group that is reasonably homogenous with respect to manifestations and prognosis. The overgrowth of PS is progressive and can be difficult to manage. The progressive overgrowth most commonly causes severe orthopaedic complications, but it can cause many other complications. One of the most common complications in patients with PS is deep venous thrombosis and pulmonary embolism, which can cause premature death. Effective management requires knowledge of the wide array of manifestations and complications of the disorder and a team approach that includes the geneticist, surgeons, and other specialists.

Entities:  

Mesh:

Year:  2006        PMID: 16883308     DOI: 10.1038/sj.ejhg.5201638

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  71 in total

1.  A child with mental retardation and asymmetrical hypertrophy of limbs.

Authors:  Sidharth Kumar Sethi; Dinesh Yadav; Parvesh Garg; Jyoti Chawla; Deepak Goyal
Journal:  Eur J Pediatr       Date:  2010-12-07       Impact factor: 3.183

2.  Allelic heterogeneity of Proteus syndrome.

Authors:  Anna Buser; Marjorie J Lindhurst; Hannah C Kondolf; Miranda R Yourick; Kim M Keppler-Noreuil; Julie C Sapp; Leslie G Biesecker
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-06-12

3.  An Illustrative Case of Neurofibromatosis Type 1 and NF1 Microdeletion.

Authors:  L A Praxedes; F M Pereira; J F Mazzeu; S S Costa; D R Bertola; C A Kim; A M Vianna-Morgante; P A Otto
Journal:  Mol Syndromol       Date:  2010-09-14

4.  Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.

Authors:  Kim M Keppler-Noreuil; Julie C Sapp; Marjorie J Lindhurst; Thomas N Darling; Jasmine Burton-Akright; Mohammadhadi Bagheri; Eva Dombi; Ashlyn Gruber; Paul F Jarosinski; Staci Martin; Neera Nathan; Scott M Paul; Ronald E Savage; Pamela L Wolters; Brian Schwartz; Brigitte C Widemann; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2019-02-22       Impact factor: 11.025

5.  A limited form of proteus syndrome with bilateral plantar cerebriform collagenomas and varicose veins secondary to a mosaic AKT1 mutation.

Authors:  Jamie S Wee; Peter S Mortimer; Marjorie J Lindhurst; Heung Chong; Leslie G Biesecker; Colin A Holden
Journal:  JAMA Dermatol       Date:  2014-09       Impact factor: 10.282

Review 6.  Advances in Skeletal Dysplasia Genetics.

Authors:  Krista A Geister; Sally A Camper
Journal:  Annu Rev Genomics Hum Genet       Date:  2015-04-22       Impact factor: 8.929

7.  Molecular regulation of limb growth.

Authors:  Karen Lyons; Marybeth Ezaki
Journal:  J Bone Joint Surg Am       Date:  2009-07       Impact factor: 5.284

8.  Excision of a large abdominal wall lipoma improved bowel passage in a Proteus syndrome patient.

Authors:  Yoshifumi Nakayama; Shinichi Kusuda; Naoki Nagata; Koji Yamaguchi
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

10.  Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome: CNS malformations and seizures may be a component of this disorder.

Authors:  Zoran S Gucev; Velibor Tasic; Aleksandra Jancevska; Marina Krstevska Konstantinova; Nada Pop-Jordanova; Zoran Trajkovski; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2008-10-15       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.